Excalipoint Therapeutics
Hong Kong, Hong Kong· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Hong Kong oncology biotech using proteomics for targeted protein degradation therapies.
Oncology
Technology Platform
An integrated proteomics and chemoproteomics platform for discovering novel E3 ligase binders and designing targeted protein degraders.
Opportunities
Potential to drug historically 'undruggable' cancer targets, opening new therapeutic avenues and high-value partnerships.
Risk Factors
The technology is novel with unproven clinical success, and molecules may face pharmacokinetic and safety challenges.
Competitive Landscape
Enters the fast-evolving targeted protein degradation arena, competing with numerous biotechs and large pharma to establish technological leadership.